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We generated immunoliposomes targeting proliferating endothelial cells by chemically coupling a single-chain Fv fragment (scFv A5)
directed against human endoglin to the liposomal surface. For this purpose, we introduced an additional cysteine residue at the C-terminus of
the scFv fragment. This scFvVfragment was expressed in soluble form in bacteria and allowed for a site-directed coupling to sulfhydryl-
reactive lipids incorporated into the lipid bilayer. The immunoliposomes (ILA5) showed rapid and strong binding to human endoglin-
expressing endothelial cells (HUVEC, HDMEC), while no binding was observed with various endoglin-negative cell lines and blood
lymphocytes. In vitro, ILA5 were stable for several hours in serum- or plasma-containing medium. Incubation of endothelial cells with ILA5
at 37 jC led to increased binding and internalisation of the liposomes as evidenced by a perinuclear accumulation. In vitro, doxorubicin-
loaded ILA5 showed an increased cytotoxicity towards endothelial cells compared to untargeted liposomes and free doxorubicin. Since the
vasculature of tumours is easily accessible to drug carrier systems, the described endothelial cell-specific immunoliposomes may be useful for
the development of efficacious and safe vascular targeting agents in cancer therapy.
D 2004 Elsevier B.V. All rights reserved.Keywords: Immunoliposome; Single-chain Fv; Vascular targeting; Endothelial cell; Doxorubicin1. Introduction
Liposomes are versatile carrier systems for the delivery
of cytotoxic drugs in tumour therapy [1]. Liposomes have
the advantage to protect the encapsulated drug from degra-
dation and elimination and to increase its serum residence
time. The incorporation of tumour-specific ligands into the
liposome surface allows active targeting to tumour cells [2].
However, active targeting of tumour cells requires passive
extravasation of the liposomes from the circulation in order
to reach the tumour cells [3]. Furthermore, recent studies
have shown that binding of targeted liposomes to tumour
cells is not sufficient to elicit a strong anti-tumour effect but
requires internalisation of the liposomes upon binding to the
cell surface [4,5].0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamen.2004.03.007
* Corresponding author. Tel.: +49-6421-3099315; fax: +49-6421-
3099313.
E-mail address: kontermann@vectron-ag.com (R.E. Kontermann).Novel approaches aim at targeting the tumour vascula-
ture rather than the tumour cells itself [6–8]. These vascular
targeting agents (VTAs) bypass the need for extravasation
from the bloodstream as endothelial cells are directly
accessible to circulating VTAs. Furthermore, the destruction
of a few endothelial cells affects a large number of tumour
cells relying on their supply. Since tumour-endothelial target
structures are expressed in all solid tumours, such VTAs are
broadly applicable.
Antibodies are versatile ligands for the generation of
vascular targeting agents and various antibodies have been
identified which recognise structures associated with angio-
genesis and neovascularisation [9]. Immunoliposomes dis-
playing scFv fragments recognising the ED-B isoform of
fibronectin expressed in the stroma and on endothelial cells
of the tumour vasculature already demonstrated targeting to
tumours and the induction of an anti-tumour response [10].
Endoglin (CD105), which is an accessory protein of the
transforming growth factor h receptor complex, has become
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vasculature [11]. Up-regulation of endoglin on proliferating
endothelial cells is associated with tumour neovascularisa-
tion [12,13]. Elevated levels of endoglin were detected in the
vasculature of different tumours, e.g. prostate cancer, breast
cancer, and melanoma [14–16]. Furthermore, endoglin ex-
pression was described to be a superior indicator of intra-
tumoural microvascular density (IMVD) compared to other
markers such as CD34 [13,17–19]. The application of anti-
endoglin immuno-conjugates already demonstrated that tar-
geting of cytotoxic agents (toxins, radionuclides) to endoglin
can lead to a long-lasting anti-tumour response [20–22].
We have recently isolated anti-endoglin scFvs from
synthetic antibody phage libraries [23,24]. These scFv mol-
ecules showed specific binding to human endothelial cells.
In the present study we used one of these anti-endoglin scFv
(scFv A5) to produce immunoliposomes targeting endoglin-
expressing cells. For this purpose, we engineered scFv
molecules displaying an additional C-terminal cysteine res-
idue for site-specific coupling to maleimide-containing lip-
osomes. We could show that these immunoliposomes exhibit
specific and efficient binding to proliferating endothelial
cells and improved cytotoxicity in vitro.2. Materials and methods
2.1. Materials
Lipids were purchased from Avanti (USA) or Nektar
(USA). Anti-His-tag antibodies were purchased from Santa
Cruz (USA). HUVECs and HDMECs were obtained from
Promocell (Germany) and maintained in EGM-2 medium.
Fluorescein-maleimide was purchased from Pierce. Bafilo-
mycin A1 was purchased from Sigma (Germany) and
carboxyfluorescein (CF) from Fluka (Germany).
2.2. Cloning of scFv-HC and scFv-CH
ScFv-HC were generated by PCR amplification of scFv
genes cloned into vector pAB1 [25] with primers LMB3 (5V-
CAG GAA ACA GCT ATG ACC-3V) and HisCysForNot
(5V-TAG TGC GGC CGC TTA GCA TGC TCC GCC ATG
GTG ATG GTG ATG ATG CGC ACG TTT GAT TTC CAG
TTT GGT-3V) and cloning of the resulting product as SfiI and
NotI fragment into pAB1. ScFv-CH was cloned accordingly
with primers LMB3 and CysHisForNot (5V-TAG TGC GGC
GCG TTA ATG GTG ATG GTG ATG ATG TGC TCC GCA
ACC CGC ACG TTT GAT TTC CAG TTT GGT-3V).
2.3. ScFv Vexpression and purification
ScFvV molecules were purified by immobilised metal-
affinity chromatography [25]. One to four litres of 2 TY,
100 Ag/ml ampicillin, 0.1% glucose were inoculated with 10
ml/l of an overnight culture of recombinant antibody-expressing bacteria and grown at 37 jC to an OD600 of
0.8. Protein expression was induced by adding 1 mM IPTG
and cells were grown for an additional 3 h at 23 jC. Cells
were harvested by centrifugation and resuspended in 30 mM
Tris–HCl pH 8, 1 mM EDTA, 20% sucrose. After 15 min,
MgSO4 was added to a final concentration of 5 mM and
cells were centrifuged at 8000 rpm for 15 min. Supernatant
was dialysed against IMAC buffer (50 mM sodium phos-
phate buffer pH 7.5, 500 mM NaCl) containing 20 mM
imidazole (IMAC loading buffer) and loaded onto a Ni-NTA
column (Qiagen) equilibrated with loading buffer. After
washing with IMAC buffer containing 35 mM imidazole
(wash buffer), scFv were eluted with IMAC buffer contain-
ing 100 mM imidazole (elution buffer). Peak fractions were
dialysed overnight against PBS. Proteins were analysed by
SDS-PAGE under reducing or non-reducing conditions and
stained either with Coomassie brilliant blue or immunoblot-
ted with an anti-His-tag antibody.
2.4. Fluorescein-coupling to scFvsV fragments
ScFvV fragments (35 Ag) were reduced by incubation
with 10 mM cysteamine in PBS, 5 mM EDTA for 1 h at 30
jC. Cysteamine was removed by gel filtration on a Sepha-
dex G25 column (Pharmacia). Fluorescein-maleimide was
added at a 25 M excess and incubated by rotating overnight
at 4 jC. Labelled proteins were separated from free fluo-
rescein-maleimide by gel filtration on a Sephadex G25
column. Protein fractions were analysed for fluorescence
using a victor2 photometer (Wallac).
2.5. Preparation of liposomes
Liposomes consisting of neutral phospholipids, choles-
terol, and functionalised coupling lipid (MPB-PE, MCC-
PE) at a molar ratio of 6:3:1 were produced from lipid films
hydrated with PBS. The final concentration was 10 Amol
lipid/ml buffer. The hydration was performed in a water bath
at 34 jC for 30 min. The resulting multilamellar vesicles
were extruded (LiposoFast Extruder) 21 times through a
polycarbonate filter (Armatis) with a pore size of 50 nm.
The liposome size was determined by dynamic light scat-
tering using a Malvern Autosizer. For fluorescence micros-
copy and FACS analysis, rhodamine-DPPE (Avanti) was
incorporated at a concentration of 0.3 mol%. CF was
encapsulatd into liposomes by adding 10 mM CF to the
hydration buffer. Unincorporated CF was removed by gel
filtration as described for TCEP.
2.6. Coupling of scFv-HC to liposomes
scFv-His-Cys (2 nmol, 50 Ag) were reduced using 2 mM
Bond-Breaker TCEP (Pierce) under argon atmosphere for 1
h at 37 jC. After gel filtration using a Sephadex G25 column,
0.5 to 2 nmol reduced scFv-HC was incubated with pre-
formedmaleimide-containing liposomes (1 Amol lipid) under
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maleimide groups were inactivated by incubation with 0.5
mM cysteine for 15 min at room temperature. Non-conjugat-
ed scFv-HC was removed by gel chromatography using a
Sepharose 4B column (Pharmacia).
2.7. FACS analysis of immunoliposomes
Cells were detached from cell culture dishes using 0.02%
EDTA (Sigma). Cells (150000 to 200000) were incubated
with liposomes (50 nmol lipid) under the indicated assay
conditions. After washing with 1% BSA in PBS, cells were
resuspended in 400 Al PBS and analysed by flow cytometry
(FACSCalibur, Becton Dickinson).
2.8. Internalisation studies
Cells grown on coverslips were washed twice with PBS
and were incubated with rhodamine-labelled liposomes (50
nmol lipid) in the presence of culture medium for 2 h at 4 or
37 jC, respectively. After washing with cold PBS, cells were
fixed using 3.7% formaldehyde in PBS and mounted with
Mowiol. Cell staining was analysed by fluorescence micros-
copy. For further studies, cells were preincubated for 30 min
at 37 jC with bafilomycin A1 at a concentration of 300 nM
before adding rhodamine-labelled ILA5 or ILA5 containing
encapsulated CF. After incubation for 1 h, cells were washed
extensively and incubated further for 1 to 20 h at 37 jC.
2.9. Remote loading of liposomes with doxorubicin and
cytotoxicity assays
Doxorubicin was loaded into uncoupled liposomes ap-
plying a transmembrane pH-gradient. First, 200 Al of the
liposome suspension (50 Amol lipid/ml) was diluted with
200 Al phosphate buffer (pH 7.4, 10 mM). To achieve the
pH gradient (intraliposomal media: pH 4, extraliposomal
media: pH 7.5), NaOH (2 M) was added to the extralipo-
somal media. This suspension was heated in a water bath to
60 jC for 5 min. Then the doxorubicin–HCl solution was
added (molar ratio dox to lipids 0.2:1) and the volume was
filled up to 1 ml with phosphate buffer to obtain a final lipid
concentration of 10 Amol/ml. The loading process was
performed for 15 min at 60 jC and for 15 min by RT. To
remove unencapsulated doxorubicin, the liposomal suspen-
sion was applied to Viva-Spins (2 ml, VivaScience) and
centrifuged for 20 min at 2400 rpm (1200 g). The encap-
sulated doxorubicin content was measured with a spectro-
photometer at 490 nm. ScFvV fragments were coupled to
dox-loaded liposomes as described above. Cells (HUVEC,
HDMEC, HEK293) were incubated with free or liposomal
doxorubicin for 2 h at 37 jC in medium at final drug
concentration between 10 nM and 10 AM. Cells were then
washed and incubated for additional 48 h. Cytotoxicity was
determined by crystal violet staining and stained cells were
quantified photometrically at 540 nm.2.10. Pharmacokinetics
Liposomes labeled with 3H-cholesterol-oleoylether (3H-
COE) were injected into the tail vein of nude mice and
blood samples were taken at the indicated time points. For
comparison, we calculated the 50% values, i.e. the time
after which 50% of the injected dose is eliminated from the
blood stream. The initial half-life (t1/2a) was calculated
using the values between 3 and 20 min and the terminal
half-life (t1/2h) was calculated using the values between 60
and 360 min.
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3.1. Generation of scFvV fragments
Single-chain Fv A5 directed against the extracellular
region of human endoglin [24] was genetically modified
to expose a cysteine residue at the C-terminus for coupling
to maleimide-containing liposomes. Two configurations
were chosen with the cysteine either in front or following
the hexahistidyl sequence used for purification. ScFv A5-
HC contained the cysteine at the C-terminus preceded by the
hexahistidyl sequence while scFv A5-CH contained the
cysteine in front of the hexahistidyl sequence (Fig. 1A
and D). Both molecules were purified from periplasmic
preparations of induced bacterial cultures in soluble form.
Yields of scFv A5-HC and scFv A5-CH were around 0.5 mg
per litre of culture, similar to yields obtained for scFv A5.
SDS-PAGE analysis revealed that the scFv fragments were
present as a mixture of monomeric and dimeric proteins
(Fig. 1B). As judged from Coomassie-stained gels, approx-
imately 50–60% of the proteins were present as monomers.
Although both scFv molecules possess an identical molec-
ular weight, scFv A5-CH had a slightly increased mobility
compared to scFv A5-HC, indicating some conformational
differences of the C-terminal region. Both antibody mole-
cules recognised endoglin in ELISA (not shown). Reactivity
of scFv A5-HC and scFv A5-CH with maleimide groups
was demonstrated by coupling fluorescein-maleimide to the
scFv constructs reduced under mild conditions prior to
coupling (Fig. 1C). In these experiments, coupling of
fluorescein-maleimide to scFv A5-HC was approximately
twice as efficient as coupling to scFv A5-CH. Thus, all
further experiments were performed with scFv A5-HC.
3.2. Coupling of scFv A5-HC to malemide-containing
liposomes
ScFv A5-HC was coupled to neutral liposome formula-
tions containing maleimide-phosphatidylethanolamine
(Mal-PE) as a coupling lipid either in the form of MCC
(maleimido-methyl-cyclohexane-carboxamide)-PE or MPB
(malemido-phenyl-butyramide)-PE. Although MCC-PE was
described to be more stable in aqueous solutions, we did not
Fig. 2. Binding analysis of A5 immunoliposomes (ILA5) to endothelial
cells (HDMECs), human melanoma cell line HBM-2, murine melanoma
cell line B16.F10, mouse fibroblasts (NIH 3T3), human embryonic kidney
cells (HEK 293), or human lymphocytes. Strong binding is observed with
HDMECs expressing high levels of endoglin, while no or only very weak
binding is observed for the other cells and cell lines. Doted line = cells
alone, thin line = unconjugated liposomes, bold line = ILA5.
Fig. 1. (A) Structure of the C-terminus of scFv A5-HC and scFv A5-CH
containing an engineering cysteine residue either in front or after the
hexahistidyl-tag. The VL sequence is underlined. (B) Purified scFv A5-CH
and scFv A5-HC contain a mixture of monomeric and dimeric molecules as
shown by SDS-PAGE analysis of non-reduced samples. (C) Coupling of
fluorescein-maleimide to scFv A5-CH or scFv A5-HC reduced with TCEP
prior to conjugation. (D) Three-dimensional model of a scFv-HC molecule.
The C-terminal extension of scFv-HC was modelled using the program
Swiss-PdbViewer [43] and was visualised with the program RasMac 2.6
(Roger Sayle, Glaxo Wellcome, UK). Cysteines are shown space-filled. The
Linker connecting the VH and the VL domain is not shown.
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ments using freshly prepared liposomes for coupling. Cou-
pling efficiency was in the range of 10–20% as judged by
Coomassie staining or immunoblotting experiments of lip-
osomes before and after separation of uncoupled scFv by gel
filtration. The average size of the A5 immunoliposomes
(ILA5) was 77F 4 nm, identical to unconjugated liposomes.
3.3. Specific binding of ILA5 to endoglin-expressing
endothelial cells
ILA5 produced by incubating 1 nmol scFvVwith 1 Amol
lipid showed strong binding to human microvascularendothelial cells (HDMEC) or human umbilical vein en-
dothelial cells (HUVEC), while no binding was observed
with various endoglin-negative cell lines (Fig. 2). As
controls, we included unconjugated liposomes. In addition,
liposomes coupled with an irrelevant scFvV (scFv M5.2;
[24]) showed only weak background binding to all cells
tested (Fig. 3A). Specificity of binding was further con-
firmed by competition experiments with soluble scFv A5
or M5.2. In this experiment, scFv A5 inhibited binding of
ILA5 in a dose-dependent manner while control scFv M5.2
showed only marginal inhibition at the highest concentra-
tion used (Fig. 3B). Further control experiments with scFv
A5-HC incubated with liposomes lacking Mal-PE did not
lead to any binding demonstrating that covalent coupling
of scFv A5-HC to the liposome surface is essential (not
shown).
Fig. 3. Specificity of binding of ILA5 to HDMECs. (A) Experiments with
unconjugated liposomes (2) or liposomes conjugated with an irrelevant
scFv (3) demonstrated specific and strong binding of ILA5 (1) to HDMECs
(0 = cells alone). (B) Competition experiments of binding of ILA5 to
HDMECs (1) with excess amounts (50 Ag/ml) of scFv A5 (2) or an
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No differences in fluorescence intensity were observed
using scFv A5-HC between 0.5 and 2 nmol per coupling
reaction (1 Amol lipid) corresponding to approximately 6–
25 scFv molecules per liposome (based on a 20% cou-
pling efficiency) (not shown). This indicates that coupling
of a few scFv molecules is sufficient for efficient binding
to the cell surface. Increased binding to HDMECs was
irrelevant scFv (3) at the same concentration (0 = cells alone).Fig. 4. (A) time course experiment of binding of ILA5 to HDMECs. Cells
were incubated with ILA5 for 0 min (1), 15 min (2) or 60 min (3) before
analysing for binding by FACS (0 = cells alone). (B) Binding of ILA5 to
HDMECs in the presence of 2% FCS (1), 10% FCS (2), or 50% FCS (3)
(0 = cells alone). (C) Binding of ILA5 to HUVECs in the presence (2) or
absence (1) of 50% human plasma (0 = cells alone). (D) Stability of ILA5 in
human plasma at 37 jC. Liposomes were incubated with human plasma for
0 h (1), 6 h (2), or 24 h (3) before analysing for binding by FACS (0 = cells
alone).seen with increasing lipid concentrations (not shown). A
time course experiment showed that binding of ILA5 to
HDMEC reached a maximum already after 15–30 min
(Fig. 4A). Binding experiments in the presence of FCS or
human plasma up to 50% did not show any reduction of
binding to HDMEC (Fig. 4B and C). A time course
experiment incubating ILA5 with 50% human plasma at
37 jC before assaying for binding to HDMEC demonstrat-
ed stability of ILA5 for several hours. A reduced binding
became evident only after 6 h of preincubation and was
further reduced after 24 h (Fig. 4D). Compared to incuba-
tion at 4 jC, binding of ILA5 to HDMEC was increased at
37 jC (Fig. 5A).Fig. 5. (A) Comparison of binding of rhodamine-labelled ILA5 (2) to
HDMECs at 4 or 37 jC (0 = cells alone, 1 = unconjugated liposomes). (B)
Fluorescence microscopy analysis of HDMECs incubated with rhodamine-
labelled ILA5 at 4 jC (left image) or at 37 jC (right image) for 2 h.
Incubation at 37 jC led to a perinuclear accumulation of fluorescent
particles, which is not found with cells incubated at 4 jC. (C) Fluorescence
microscopy analysis of HUVECs incubated with rhodamine-labelled ILA5
for 20 h in the presence or absence of 300 nM bafilomycin.
Table 1
Cytotoxicity of free or encapsulated doxorubicin on various cell types
after 2 h of incubation with drug and analysed after incubation for
additional 48 h without drug (IC50 values are indicated in AM)
Formulation HUVEC HDMEC HEK 293
Free dox 3 1.4 0.4
ILA5 dox 1.2 0.1 >10
Liposomal dox >3 >10 >10
ILA5 >10 >10 >10
iophysica Acta 1663 (2004) 158–166 1633.5. Internalisation of ILA5
Incubation of endothelial cells with rhodamine-labelled
ILA5 at 37 jC led to internalisation of the liposomes as
visualised by a perinuclear accumulation of fluorescence
after incubation for 2 h at 37 jC (Fig. 5B). No such
staining was seen after incubation at 4 jC. Intracellular
accumulation of rhodamine-labelled ILA5 was still visible
after 2 to 4 h of incubation in the presence of bafilomy-
cin A1, an inhibitor of vacuolar-type H+-ATPases in-
volved in acidification of endosomes. After prolonged
incubation (20 h) cells treated with bafilomycin showed
an increased vesicular accumulation of the fluorescent dye
compared to untreated cells, which showed a weaker and
more homogenous distribution (Fig. 5C). These results
were confirmed using ILA5 containing encapsulated CF
(not shown), indicating that endosomal trafficking of
liposomal lipids and encapsulated compounds is blocked
by bafilomycin.
3.6. In vitro cytotoxicity of doxorubicin-A5
immunoliposomes
Fluorescence microscopy of HUVECs incubated for 2
h with doxorubicin-loaded ILA5 or untargeted liposomes
showed an increased intracellular and nuclear fluores-
cence, indicating increased uptake of doxorubicin by
ILA5 (Fig. 6). This was also reflected by an increased
cytotoxicity of doxorubicin-loaded ILA5 towards endothe-
lial cells (HUVEC, HDMEC) (Table 1). In this assay, cells
were incubated for 2 h with liposomes and for additional
48 h after removing unbound liposomes. These assay
conditions were chosen to minimise possible cytotoxic
effects of doxorubicin released from the liposomes by
leakage. No cytotoxic effects were observed after incuba-
tion of HEK293 included as a non-targeted cell type. In
addition, untargeted doxorubicin-loaded liposomes or
unloaded ILA5 showed no cytotoxicity within the ana-
lysed concentration range (Table 1). In these assays
doxorubicin-loaded ILA5 were approximately 3- to 10-
fold more potent in killing endothelial cells than free
doxorubicin.
T. Vo¨lkel et al. / Biochimica et BFig. 6. Fluorescence microscopy of HUVECs incubated for 2 h with
doxorubicin-loaded untargeted liposomes (A) or doxorubicin-loaded ILA5
(B). This experiment showed an increased intracellular and nuclear
fluorescence after incubation with doxorubicin-loaded ILA5.3.7. Pharmacokinetics of A5 immunoliposomes
Analysis of the blood circulation time of 3H-labelled
ILA5 or unconjugated liposomes containing the same
amount of coupling lipid showed rapid clearance of these
liposomes from the circulation with 50% values < 3 min. In
contrast, the same liposomal formulation without coupling
lipid had 50% values of approximately 1.5 h (t1/2a = 45 min,
t1/2h = 9 h), indicating that Mal-PE is responsible for the
drastically reduced circulation time.4. Discussion
Using a genetically engineered scFvVfragment exposing
an additional cysteine residue at its C-terminus, we were
able to generate immunoliposomes targeting endoglin-
expressing endothelial cells. The application of scFvV frag-
ments allows for a site-directed coupling via a single
reactive thiol group. Since the C-terminus of a scFv mole-
cule is located opposite the antigen-binding site. this allows
unhindered binding to the antigen (Fig. 1D). In addition, it
avoids aggregate formation which is often observed using
coupling through reactive groups such as q-amino groups of
lysines exposed in scFv molecules at multiple sites.
The scFv A5-HC fragment could be purified in soluble
form from the periplasm of bacterial cultures. Thus, the
presence of an additional cysteine residue does not lead to
the formation of insoluble aggregates as observed previous-
ly for a murine scFvVexpressed in bacteria [26]. This might
be attributable to the codon-optimised scFv sequence and
the isolation of scFv A5 from a phage display library [24].
Due to the oxidising milieu in the periplasm, a substantial
amount of the scFvV fragment was found to be present as
disulfide-linked dimers. This dimer formation was also
observed for various other scFvV fragments expressed in
prokaryotic or eukaryotic expression systems [4,10,27]. A
recent study with an anti-erbB2 scFvVmolecule used for the
generation of PEGylated immunoliposomes showed that
only 10% of the purified antibody molecules had a free
thiol group [4]. Hence, as observed in our study, coupling to
liposomes containing functionalised lipids required reduc-
tion of the antibody molecules under mild conditions.
Coupling of scFv A5-HC to preformed liposomes yielded
a coupling efficiency of approximately 10–20%. Similar
values were also described for a scFvVmolecule directed
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maleimide-PEG liposomes [10]. In addition, similar values
were found in a comparative analysis for MPB-PE and other
maleimide-containing lipids with a short and nonpolar
spacer demonstrating the influence of spacer length and
polarity on coupling efficiency [28]. Thus, the observed low
coupling efficiency to MPB-PE or MCC-PE may be attrib-
utable to the close distance of the maleimide group to the
liposome surface resulting in an insufficient presentation to
reactive ligands.
A5 immunoliposomes showed strong and specific bind-
ing to endoglin-expressing endothelial cells, identical in
binding activity to scFv A5 [24]. Coupling of 6–25 scFv
A5 molecules to liposomes confered efficient binding. In
another study, Park et al. [29] found that PEGylated lip-
osomes containing 30–40 anti-HER2 scFv molecules per
liposome showed optimal binding to erbB2-expressing
tumour cells. In contrast, strongest internalisation was
already observed at a density of 25–30 scFv molecules
per liposomes [4]. These studies demonstrate that coupling
of only a few scFv molecules is sufficient to mediate strong
binding and internalisation into target cells.
Our studies using bafilomycin as inhibitor of endosome
acidification and endosome–lysosome fusion [30] showed
an increased granular accumulation within the cells in the
presence of bafilomycin, which was most prominent after
prolonged incubation. This finding is in accordance with an
uptake of the liposomes by endocytosis and processing in
the lysosomal compartment [31,32]. An intracellular deliv-
ery of encapsulated compounds and release into the cyto-
plasm was further confirmed with ILA5-Dox liposomes.
However, we cannot exclude at present that other mecha-
nisms, e.g. plasma membrane fusion, macropinocytosis or
external release, contribute to uptake of encapsulated com-
pounds or lipids into the cells [33,34].
Binding of ILA5 to endothelial cells was stable under
physiological conditions and only incubation of A5 immu-
noliposomes in human plasma at 37 jC for a prolonged
period of time reduced the binding activity. This finding
indicates that the binding activity of the scFv molecules is
little affected by the presence of plasma components. How-
ever, our preliminary data show that the in vivo pharmaco-
kinetic properties of the liposomes are drastically influenced
by the coupling lipids. This finding further demonstrates the
negative influence of the functionalised lipids and the
coupling chemistry on the in vivo behaviour of the liposomes
[35–37]. These limitations might be overcome by the use of
PEGylated liposomes, a reduced number of coupling lipids
or alternative approaches such as post-insertion methods
[4,38]. In preliminary experiments we could already show
that PEGylated A5 immunoliposomes also exhibit strong
binding activity for endothelial cells (not shown). Further
studies with PEGylated A5 immunoliposomes have to dem-
onstrate the beneficial effects on pharmacokinetics.
Compared to murine IgG molecules or fragments thereof,
human scFv molecules should improve the in vivo efficacyof immunoliposomes due to the lack of Fc-mediated clear-
ance and an absent or reduced neutralising immune response
[39,40], although a neutralising anti-idiotypic immune re-
sponse cannot be ruled out. Currently, there is no data
available on the behaviour of immunoliposomes composed
of human scFv fragments upon repeated injection into
immunocompetent animals or in clinical settings.
A5 immunoliposomes will allow for the targeting of
tumour endothelial cells expressing endoglin. Several stud-
ies have established that endoglin is up-regulated in the
vasculature of solid tumours and a versatile marker for
tumour angiogenesis and intratumoural microvascular den-
sity [11–17]. Importantly, binding of A5 immunoliposomes
resulted in internalisation of the carrier systems. This finding
is in accordance with studies applying FITC-labelled anti-
endoglin antibodies, which described internalisation into
mouse endothelial cells [21]. Thus, A5 immunoliposomes
should be useful to deliver therapeutic drugs into tumour
endothelial cells as already demonstrated in our in vitro
experiments. The species specificity of scFv A5 [24],
however, puts obstacles on the in vivo analysis in animal
models of A5 immunoliposomes as human tumour xeno-
grafts are supported by the host vasculature. One possibility
is the use of a chimaeric human/mouse skin model in which
human skin is transplanted onto immunodeficient mice [41].
Tumours grown in the human skin transplant contain vessels
composed of a mixture of murine and human endothelial
cells. Such a tumour model was already employed to analyse
anti-tumour effects of anti-human endoglin monoclonal anti-
bodies, which cross-react only very weakly with murine
endothelial cells [42]. Alternatively, endoglin knock-out
knock-in animals could be used to analyse endoglin-target-
ing antibodies and immunoliposomes.
In summary, we applied an engineered recombinant
human antibody fragment for the generation of immunoli-
posomes for the targeting of endoglin-expressing proliferat-
ing endothelial cells. Since the vasculature of tumours is
easily accessible to drug carrier systems, endoglin-targeting
immunoliposomes may be useful for the development of
efficacious and safe vascular targeting agents in cancer
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